{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:40:49Z","timestamp":1773510049758,"version":"3.50.1"},"reference-count":17,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T00:00:00Z","timestamp":1486771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100004776","name":"Faculty of Medicine, Chulalongkorn University","doi-asserted-by":"publisher","award":["Ratchadapiseksompoch Fund"],"award-info":[{"award-number":["Ratchadapiseksompoch Fund"]}],"id":[{"id":"10.13039\/501100004776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Risk assessment to identify patients at risk for hereditary ovarian cancer is important. The objectives of this study were to evaluate the frequency of high\u2010risk epithelial ovarian cancer (EOC) patients and the frequency of germline mutation in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 335 patients with histologically confirmed non\u2010mucinous EOC were included. High\u2010risk patients were defined as patients who had: (i) significant family history of breast\/ovarian\/colorectal\/endometrial cancers; (ii) synchronous breast\/endometrial\/colorectal cancer; or (iii) high\u2010grade serous carcinoma. Germline mutation was evaluated by Next Generation Sequencing system with the 27\u2010genes panel.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 94 patients (28.1%) were high\u2010risk patients, 5.1% had significant family history of cancers, 4.2% had synchronous primary cancers, and 22.1% had high\u2010grade serous carcinoma. Germline mutation was detected in 10 of 35 patients (28.6%). Six germline mutations (17.1%) occurred in homologous recombination (HR) genes; these included three (8.6%) in <jats:italic>BRCA1<\/jats:italic>, one (2.9%) in <jats:italic>BRCA2<\/jats:italic>, and two (5.7%) in other HR genes (<jats:italic>CHEK2<\/jats:italic> and <jats:italic>RAD1C<\/jats:italic>). Three patients (8.6%) had <jats:italic>MMR<\/jats:italic> gene mutations (one <jats:italic>MLH1<\/jats:italic> and two <jats:italic>MSH2<\/jats:italic>) and one patient (2.9%) had other gene mutation (<jats:italic>MUTYH<\/jats:italic>). Of the 10 patients with germline mutation, 40% of patients had no significant family history of cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Up to 30% of EOC patients had risk factors for hereditary ovarian cancer. Germline mutation was identified in 28.6% of patients (11.4% <jats:italic>BRCA<\/jats:italic> mutation, 5.7% other HR genes mutation, 8.6% <jats:italic>MMR<\/jats:italic> mutation, and 2.9% mutation in other gene). The high cost of genetic testing is an important barrier. Selected patients with high\u2010risk factors might be initially considered for genetic testing in a limited\u2010resource setting.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jog.13287","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T13:06:36Z","timestamp":1486818396000},"page":"929-934","source":"Crossref","is-referenced-by-count":7,"title":["High\u2010risk epithelial ovarian cancer patients for hereditary ovarian cancer"],"prefix":"10.1111","volume":"43","author":[{"given":"Seksit","family":"Chirasophon","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine Chulalongkorn University  Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarinee","family":"Manchana","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine Chulalongkorn University and King Chulalongkorn Memorial Hospital  Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinachote","family":"Teerapakpinyo","sequence":"additional","affiliation":[{"name":"Chulalongkorn GenePRO Center, Research Affairs, Faculty of Medicine Chulalongkorn University  Bangkok Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,2,11]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"957","article-title":"American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins\u2014Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologist","volume":"113","author":"ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome","year":"2009","journal-title":"Obstet Gynecol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000466373.71146.51"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.005"},{"key":"e_1_2_7_5_1","unstructured":"FerlayJ SoerjomataramI ErvikMet al.GLOBOCAN 2012 v1.0 Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon France: International Agency for Research on Cancer;2013. [Cited 13 July 2016.] Available from URL:http:\/\/globocan.iarc.fr"},{"key":"e_1_2_7_6_1","first-page":"117","volume-title":"World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs","author":"Lee KR","year":"2003"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200404000-00009"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0607-3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.8545"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.7314\/APJCP.2014.15.18.7929"},{"key":"e_1_2_7_12_1","unstructured":"National Comprehensive Cancer Network.Genetic\/familial high\u2010risk assessment: Breast and ovarian(Version 2 2016). [Cited 13 July 2016.] Available from URL:http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_screening.pdf"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.009"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1115052108"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2287"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2011.01.020"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddu172"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30197"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjog.13287","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.13287","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T15:35:20Z","timestamp":1696174520000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/jog.13287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,11]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/jog.13287"],"URL":"https:\/\/doi.org\/10.1111\/jog.13287","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"value":"1341-8076","type":"print"},{"value":"1447-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,11]]}}}